Chronic active hepatitis associated with etretinate therapy

Weiss, Virginia C.; Layden, Thomas J.; Spinowitz, Alan L.; Buys, Cunera M.; Nemchausky, Bernard A.; West, Dennis P.; Emmons, Karen M.

doi:10.1111/j.1365-2133.1985.tb15269.x

Cited by 38 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the widely used oral anti‐psoriatic methotrexate is contraindicated in liver disease 86 . Systemic retinoids have been associated with reversible increased liver function test results, 87 but may be used relatively safely if treatment is initiated after serum aminotransferase levels have returned to normal 20 . Systemic corticosteroids and cyclosporine are effective, but the risk of a flare of pustular psoriasis in the former and potentiation of viral hepatitis due to immunosuppression in both are major drawbacks 20,86 .…”

Section: Treatment and Management Recommendationsmentioning

confidence: 99%

Induction and exacerbation of psoriasis with Interferon‐alpha therapy for hepatitis C: A review and analysis of 36 cases

Afshar

Martinez

Gallo

et al. 2012

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Interferon-alpha (IFN-α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN-α is increasingly recognized, but the distinct associated features, etiology, and management have not been reviewed. Objective To review all published cases of hepatitis C patients who developed psoriasis while receiving IFN-α therapy. Methods The review was conducted by searching the PubMed database using the keywords “hepatitis C” AND “psoriasis.” In addition, references to additional publications not indexed for PubMed were followed to obtain a complete record of published data. Results We identified 32 publications describing 36 subjects who developed a psoriatic eruption while receiving IFN-α therapy for hepatitis C. Topical therapies were a commonly employed treatment modality but led to resolution in only 30% of cases in which they were employed solely. Cessation of IFN-α therapy led to resolution in 93% of cases. 100% of those who developed psoriasis while on IFN-α therapy responded to systemic therapy and were able to continue the drug. Conclusion Further studies and analysis of IFN-α-induced lesions are necessary to clarify the role of IFN-α and the hepatitis C virus in the development of psoriatic lesions.

show abstract

Section: Treatment and Management Recommendationsmentioning

confidence: 99%

Induction and exacerbation of psoriasis with Interferon‐alpha therapy for hepatitis C: A review and analysis of 36 cases

Afshar

Martinez

Gallo

et al. 2012

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…In previous studies, oral retinoids have been associated with increased liver function test results and few, isolated cases of long-term hepatotoxic sequelae. [28][29][30] These abnormal liver function test results are typically reversible, either after discontinuation of the oral retinoid or sometimes even with sustained use. 14,31 The package insert describes several potentially serious side effects, including yellowing of skin and sclera, nausea and vomiting, loss of appetite, and dark urine.…”

Section: Acitretinmentioning

confidence: 99%

Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation

Frankel

Voorhees

Hsu

et al. 2009

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Etretin Therapy for Severe Psoriasis

Kingston¹

1987

Arch Dermatol

View full text Add to dashboard Cite

We have investigated the clinical responses of 21 patients with severe psoriasis to therapy with etretin, a metabolite of etretinate. In a preliminary double-blind dose-finding study, the optimum dose of etretin was determined to be 50 mg/d (mean, 0.66 mg/kg/d). In an open study, patients receiving etretin therapy were followed up for a minimum of six months. An excellent or good response (greater than 50% clearance) was obtained in 18 of 21 patients. The incidence of mucocutaneous side effects from etretin therapy was similar to that previously reported with etretinate therapy. As a group, patients who received etretin therapy for six or more months showed no significant aberrations from normal levels of serum lipids or serum liver enzymes. However, five patients had mild elevation of liver enzymes or blood lipids, which were corrected by dose reduction. Etretin showed equivalent efficacy to that previously reported with etretinate in severe recalcitrant plaque psoriasis vulgaris. Taken with the reportedly more rapid clearance of etretin from the body, there may be clinical advantages of the use of etretin over the use of etretinate.

show abstract

Chronic active hepatitis associated with etretinate therapy

Cited by 38 publications

References 12 publications

Induction and exacerbation of psoriasis with Interferon‐alpha therapy for hepatitis C: A review and analysis of 36 cases

Induction and exacerbation of psoriasis with Interferon‐alpha therapy for hepatitis C: A review and analysis of 36 cases

Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation

Etretin Therapy for Severe Psoriasis

Contact Info

Product

Resources

About